https://www.selleckchem.com/pr....oducts/bay-87-2243.h
The secondary outcomes include the variations in the scores pertaining to the Hospital Anxiety and Depression Scale and the EuroQoL 5-dimension 5-level Questionnaire and the results of the liver and kidney function tests. This trial will assess the efficacy of modified BXD in improving the clinical symptoms and quality of life of the patients suffering from Wei-Pi syndrome. ClinicalTrials.gov NCT04398888 . Registered on May 21, 2020. ClinicalTrials.gov NCT04398888 . Registered on May 21, 2020. Combination of mesenchymal stem cells (